The Oswaldo Cruz Foundation (Fiocruz) announced that it has signed a technological cooperation agreement with the American pharmaceutical company Merck Sharp & Dohme (MSD) to produce the first oral antiviral drug for the treatment of Covid-19.
The drug has already been evaluated by the National Health Surveillance Agency (Anvisa) in November and, this week, received authorization for emergency use of molnupiravir, the name given to the drug.
At this first moment, Fiocruz will be responsible for importing, administering, testing, storing, packaging, labeling, releasing and supplying the antiviral against Covid-19 to the Unified Health System (SUS).
Over the next two years, technology transfer will be carried out so that production becomes 100% national. The process will take place based on the analysis of demand and technical conditions of drug administration in the SUS.
Fiocruz will also be able to carry out clinical studies to verify the effectiveness in a possible prophylactic use for Covid-19, in addition to experimental studies of the drug’s activity against viruses such as dengue and chikungunya.
“We’ve been talking to MSD for over a year and following all the evolution of tests and results, in the crowd, because we had a pandemic and an entire population to treat. I think we have arrived at a very robust document, not only in the sense of bringing yet another tool to combat covid-19, but also to internalize the product and use it for other important diseases for SUS”.
Via: Agência Brasil
Have you watched the new videos on YouTube from Olhar Digital? Subscribe to the channel!